Skip to main content

Advertisement

SpringerLink
Log in

Impact of 18F-FDG-PET/CT on surgical management in patients with advanced melanoma: an outcome based analysis

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

To evaluate the influence of 18F-FDG-PET/CT on clinical decision making and outcome in advanced melanoma patients planned for radical metastasectomy.

Methods and materials

A cohort of 333 patients with mainly stage III/IV melanoma having a PET/CT for clinical reasons was prospectively enrolled in our oncologic PET/CT registry between 2013 and 2015. Referring physicians completed questionnaires regarding their intended management for each patient before and after PET/CT. Management changes after PET/CT were classified as major and minor changes. A subgroup of 107 patients (stage I, N = 5; stage II, N = 3; stage III, N = 42; stage IV, N = 57) was planned for complete metastasectomy initially, based on conventional imaging. Management changes and outcome were evaluated by linkage with the information obtained from patients’ medical records.

Results

In 28 of 107 patients (26%), the surgical treatment plan remained unchanged after PET/CT. In 24 patients (22%), minor changes were performed, such as enlargement or reduction of the surgical field. In 55 patients (51%, 95% CI 42%-61%) major changes of the intended treatment plan occurred; of those, 20 patients (19%) were classified to be tumor-free with PET/CT, 32 patients (30%) were found to have multiple previously unrecognized metastases and had to be treated by systemic therapy, three patients (3%) had to be changed to palliative radiotherapy or isolated extremity perfusion. The 1-year and 2-year overall survival (OS) in patients with complete metastasectomy (N = 52) was 90% and 79%, respectively. Systemically treated patients (N = 32) resulted in 1-year OS of 72% and 2-year OS of 61%. Eleven of 32 patients (34%) with systemic therapy experienced a complete response. Until December 2016, all 20 patients classified as tumor-free by PET/CT were alive.

Conclusion

The study confirms the high impact of PET/CT on clinical management in patients with advanced melanoma planned for radical metastasectomy. PET/CT resulted in frequent management changes, preventing futile surgery in half of the patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol : Off J Am Soc Clin Oncol. 2009;27:6199–206. doi:10.1200/jco.2009.23.4799.

    Article  Google Scholar 

  2. Weide B, Elsasser M, Buttner P, Pflugfelder A, Leiter U, Eigentler TK, et al. Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis. Br J Cancer. 2012;107:422–8. doi:10.1038/bjc.2012.306.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Kroon BB. Surgery for distant metastatic melanoma improves survival. Ann Surg Oncol. 2012;19:2426–7. doi:10.1245/s10434-012-2399-y.

    Article  PubMed  Google Scholar 

  4. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med. 2004;351:998–1012. doi:10.1056/NEJMra041245.

    Article  CAS  PubMed  Google Scholar 

  5. Caudle AS, Ross MI. Metastasectomy for stage IV melanoma: for whom and how much? Surg Oncol Clin N Am. 2011;20:133–44. doi:10.1016/j.soc.2010.09.010.

    Article  PubMed  Google Scholar 

  6. Weide B, Martens A, Hassel JC, Berking C, Postow MA, Bisschop K, et al. Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. Clin Cancer Res : Off J Am Assoc Cancer Res. 2016. doi:10.1158/1078-0432.ccr-16-0127.

    Google Scholar 

  7. Ugurel S, Rohmel J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A, et al. Survival of patients with advanced metastatic melanoma: The impact of novel therapies. Eur J Cancer (Oxford, England : 1990). 2016;53:125–34. doi:10.1016/j.ejca.2015.09.013.

    Article  Google Scholar 

  8. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–16. doi:10.1056/NEJMoa1103782.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (London, England). 2012;380:358–65. doi:10.1016/s0140-6736(12)60868-x.

    Article  CAS  Google Scholar 

  10. Larkin J, Ascierto PA, Dréno B, Atkinson V, Liszkay G, Maio M, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371:1867–76. doi:10.1056/NEJMoa1408868.

    Article  PubMed  Google Scholar 

  11. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371:1877–88. doi:10.1056/NEJMoa1406037.

    Article  PubMed  Google Scholar 

  12. Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C, et al. Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma. N Engl J Med. 2011;364:2517–26. doi:10.1056/NEJMoa1104621.

    Article  CAS  PubMed  Google Scholar 

  13. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521–32. doi:10.1056/NEJMoa1503093.

    Article  CAS  PubMed  Google Scholar 

  14. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320–30. doi:10.1056/NEJMoa1412082.

    Article  CAS  PubMed  Google Scholar 

  15. Xing Y, Bronstein Y, Ross MI, Askew RL, Lee JE, Gershenwald JE, et al. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst. 2011;103:129–42. doi:10.1093/jnci/djq455.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Vach W, Hoilund-Carlsen PF, Gerke O, Weber WA. Generating evidence for clinical benefit of PET/CT in diagnosing cancer patients. J Nucl Med : Off Publ, Soc Nucl Med. 2011;52 Suppl 2:77s–85s. doi:10.2967/jnumed.110.085704.

    Article  Google Scholar 

  17. MSAC. Guidelines for the assessment of diagnostic technologies. Canberra, ACT: Commonwealth of Australia; 2005.

    Google Scholar 

  18. Fryback DG, Thornbury JR. The efficacy of diagnostic imaging. Med Decis Making : Int J Soc Med Decis Making. 1991;11:88–94.

    Article  CAS  Google Scholar 

  19. Pflugfelder A, Kochs C, Blum A, Capellaro M, Czeschik C, Dettenborn T, et al. Malignant melanoma S3-guideline “diagnosis, therapy and follow-up of melanoma”. J Dtsch Dermatol Ges = J German Soc Dermatol : JDDG. 2013;11 Suppl 6:1–116. doi:10.1111/ddg.12113_suppl.

    Google Scholar 

  20. Dalrymple-Hay MJ, Rome PD, Kennedy C, Fulham M, McCaughan BC. Pulmonary metastatic melanoma -- the survival benefit associated with positron emission tomography scanning. Eur J Cardio-thoracic Surg : Off J Eur Assoc Cardio-thoracic Surg. 2002;21:611–4. discussion 4-5.

    Article  CAS  Google Scholar 

  21. Bronstein Y, Ng CS, Rohren E, Ross MI, Lee JE, Cormier J, et al. PET/CT in the management of patients with stage IIIC and IV metastatic melanoma considered candidates for surgery: evaluation of the additive value after conventional imaging. AJR Am J Roentgenol. 2012;198:902–8. doi:10.2214/ajr.11.7280.

    Article  PubMed  Google Scholar 

  22. Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54. doi:10.1007/s00259-014-2961-x.

    Article  CAS  PubMed  Google Scholar 

  23. Singnurkar A, Wang J, Joshua AM, Langer DL, Metser U. 18F-FDG-PET/CT in the staging and management of melanoma: a prospective multicenter ontario PET registry study. Clin Nucl Med. 2016;41:189–93. doi:10.1097/rlu.0000000000000996.

    Article  PubMed  Google Scholar 

  24. Bastiaannet E, Wobbes T, Hoekstra OS, van der Jagt EJ, Brouwers AH, Koelemij R, et al. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment. J Clin Oncol : Off J Am Soc Clin Oncol. 2009;27:4774–80. doi:10.1200/jco.2008.20.1822.

    Article  Google Scholar 

  25. Schüle S-C, Eigentler TK, Garbe C, la Fougère C, Nikolaou K, Pfannenberg C. Influence of 18F-FDG PET/CT on therapy management in patients with stage III/IV malignant melanoma. Eur J Nucl Med Mol Imaging. 2016;43:482–8. doi:10.1007/s00259-015-3187-2.

    Article  PubMed  Google Scholar 

  26. Gulec SA, Faries MB, Lee CC, Kirgan D, Glass C, Morton DL, et al. The role of fluorine-18 deoxyglucose positron emission tomography in the management of patients with metastatic melanoma: impact on surgical decision making. Clin Nucl Med. 2003;28:961–5. doi:10.1097/01.rlu.0000099805.36471.aa.

    Article  PubMed  Google Scholar 

  27. Forschner A, Eichner F, Amaral T, Keim U, Garbe C, Eigentler TK. Improvement of overall survival in stage IV melanoma patients during 2011-2014: analysis of real-world data in 441 patients of the German Central Malignant Melanoma Registry (CMMR). J Cancer Res Clin Oncol. 2016. doi:10.1007/s00432-016-2309-y.

    PubMed  Google Scholar 

  28. Leeneman B, Franken MG, Jochems A, Schouwenburg MG, Wouters MW, Van den Eertwegh AJ, et al. Improved survival in patients with advanced melanoma in real-world clinical practice: first results of the dutch melanoma treatment registry. Value Health : J Int Soc Pharmacoecon Outcomes Res. 2015;18:A440–1. doi:10.1016/j.jval.2015.09.1079.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Eberhard-Karls-University Tuebingen, Liebermeisterstr. 25, 72076, Tübingen, Germany

    Andrea Forschner, Ulrike Keim, Thomas Kurt Eigentler & Claus Garbe

  2. Department of Diagnostic and Interventional Radiology, Eberhard-Karls-University Tuebingen, Tübingen, Germany

    Susann-Cathrin Olthof, Brigitte Gückel, Konstantin Nikolaou & Christina Pfannenberg

  3. Department of Clinical Epidemiology and Applied Biostatistics, Eberhard-Karls-University Tuebingen, Tübingen, Germany

    Peter Martus

  4. Institute of Medical Biometry and Statistics, University Freiburg, Freiburg, Germany

    Werner Vach

  5. Department of Nuclear Medicine and Clinical Molecular Imaging, Eberhard-Karls-University Tuebingen, Tübingen, Germany

    Christian la Fougère

Authors
  1. Andrea Forschner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susann-Cathrin Olthof
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Brigitte Gückel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peter Martus
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Werner Vach
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Christian la Fougère
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Konstantin Nikolaou
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ulrike Keim
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Thomas Kurt Eigentler
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Claus Garbe
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Christina Pfannenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrea Forschner.

Ethics declarations

Conflict of interest statement

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

This study was approved by the local ethics committee of the University of Tuebingen (reference number 064/2013B01).

Informed consent

Informed consent was obtained from all patients included in this study.

Funding

The study was funded by the young scientists’ programme of the German network ‘Health Services Research Baden-Württemberg’ of the Ministry of Science, Research and Arts in collaboration with the Ministry of Employment and Social Order, Family, Women and Senior Citizens, Baden-Württemberg.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Forschner, A., Olthof, SC., Gückel, B. et al. Impact of 18F-FDG-PET/CT on surgical management in patients with advanced melanoma: an outcome based analysis. Eur J Nucl Med Mol Imaging 44, 1312–1318 (2017). https://doi.org/10.1007/s00259-017-3674-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-017-3674-8

Keywords

Search

Navigation